Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional 5-Fluorouracil With or Without Topical Calcipotriene in Squamous Cell Carcinoma of the Lower Extremities
NCT03370406Phase 1Recruiting
- Start
- Aug 2018
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluorouracil and calcipotriol in squamous cell carcinoma (SCC) (3 arms). Primary endpoint: Dose Limiting Toxicity at 84 days. Started Aug 2018; status: recruiting.
02
Drugs
fluorouracilcalcipotriol
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT03370406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370406.